The FDA guidelines for Wegovy recommend starting the medication at 0.25 mg once weekly for four weeks and increasing the dose to 0.5 mg once weekly for the next four weeks before increasing to 1 mg once weekly for four weeks, then 1.7 mg once weekly for 4 weeks, and then 2.4 mg once weekly
At a glance Retatrutide is an investigational weekly injection from Eli Lilly, not yet licensed in the UK It targets three hormone receptors at once GLP-1, GIP and glucagon earning it the nickname "triple G" It reduces appetite, improves blood sugar, and appears to nudge resting energy expenditure upwards Phase 2 trial participants lost an average of around 24% of body weight over 48 weeks at the top dose Side effects mirror existing GLP-1 medications: nausea, mild gut symptoms, reduced appetite Expected UK approval is 18-24 months away pending Phase 3 results and MHRA review The basics: what retatrutide is Retatrutide is an investigational weekly injection being developed by Eli Lilly for weight loss and related metabolic conditions
( B ) Cell typespecific expression of F2rl1 and PAR2-activating proteases St14 , Tmprss2 , and F10
Research shows that up to 3040% of weight lost on GLP-1 drugs can come from lean body mass (i.e., muscle), not just fat
95% CI 2.6, 1.6) and greater at 12 months ( 2.8 kg
